Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), the psychedelic medicines-focused group, revealed that a poster on its lead compound MSP-1014 will be presented at the prestigious Society for Neuroscience (SFN) 50th Annual Meeting: Neuroscience 2021, being held virtually this year.
In focus will be the pre-clinical benchmarking data for Mindset's optimized psilocybin analog MSP-1014 compared to first-generation psychedelic compounds.
Presented by Dr Guy Higgins, from Mindset’s scientific advisory board and the Chief Scientific Officer of InterVivo Solutions, it is titled: 'Characterisation of Behavioural, Safety and Pharmacokinetics Properties of Psilocybin and Psilocin in Rodents'.
"Mindset has developed an impressive library of preclinical data measuring the safety and efficacy of psychedelic drugs and our next-generation analogs," said Joseph Araujo, the chief scientific officer of Mindset.
"The presentation of Mindset’s data at the prestigious SFN annual meeting signifies an important recognition by the scientific community that we are applying rigorous standards and protocols for our preclinical studies.
"We remain committed to sharing our findings with the goal of advancing the industry’s understanding of the therapeutic benefits of psychedelic drugs and their potential to address a range of central nervous system disorders."
MSP-1014 is a psilocybin-based from Mindset’s Family 1 of novel, patent-pending psychedelic compounds.
It was the first candidate to progress towards human clinical trials for treatment-resistant depression and end-of-life cancer angst after displaying high rates of success through a comprehensive range of specialized preclinical in vitro and in vivo tests.
The Neuroscience meeting is being held virtually between November 8 and November 11 this year.
Contact the author at giles@proactiveinvestors.com